Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 4/20 | 0.47 |
| ▸ | MMP3 | P08254 | 4/20 | 0.47 |
| ▸ | MMP9 | P14780 | 4/20 | 0.47 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | CPA2 | P48052 | 1/20 | 0.42 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | NPY1R | P25929 | 2/20 | 0.41 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23052583 | 1.00 | MMP1 (0.47) | MMP1MMP3MMP9TLR2MMP2 | |
| SCHEMBL21736756 | 0.87 | CPB2 (0.46) | MMP1MMP3MMP9TLR2MMP2 | |
| SCHEMBL21081675 | 0.86 | HTR2A (0.47) | MMP3MMP2CPB2LMNATSHR | |
| SCHEMBL21081698 | 0.86 | HTR2A (0.47) | MMP3MMP2CPB2LMNATSHR | |
| SCHEMBL30426371 | 0.84 | MMP2 (0.53) | MMP1MMP3MMP9MMP2CPB2 | |
| SCHEMBL21742959 | 0.82 | TSHR (0.39) | MMP3MMP2LMNATSHRNPY1R | |
| SCHEMBL13598088 | 0.81 | MMP2 (0.56) | MMP2CPB2LMNA | |
| SCHEMBL11518823 | 0.81 | MMP2 (0.56) | MMP2CPB2LMNA | |
| SCHEMBL24701921 | 0.80 | NPC1 (0.52) | MMP1MMP3TLR2MMP2LMNA | |
| SCHEMBL23618430 | 0.80 | NPC1 (0.52) | MMP1MMP3TLR2MMP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2022-09-01 | — | — | US | disclosed |
| US-20210060172-A1 | THERAPEUTIC DENDRIMERS | ASTRAZENECA AB (SE) | 2021-03-04 | — | — | US | disclosed |
| WO-2020035816-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | ASTRAZENECA AB (SE) | 2020-02-20 | — | — | WO | disclosed |
| WO-2020035815-A1 | DENDRIMER FORMULATIONS | ASTRAZENECA AB (SE) | 2020-02-20 | — | — | WO | disclosed |
| US-10314920-B2 | Therapeutic dendrimers | ASTRAZENECA AB (SE) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10314920-B2 | Therapeutic dendrimers | CD44, ITGAV, FOLR1 | MMP1 3230/4885MMP3 2083/4885MMP9 1504/4885 |
| US-20220273807-A1 | CONJUGATES FOR USE IN METHODS OF TREATING CANCER | CD44, FOLH1, SLC17A5 | MMP1 1535/4885MMP3 924/4885MMP9 1519/4885 |
| US-20210060172-A1 | THERAPEUTIC DENDRIMERS | CD44, ITGAV, FOLR1 | MMP1 3230/4885MMP3 2083/4885MMP9 1504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.